Does C50.912 require prior authorization?

No, C50.912 does not require prior authorization (high confidence). Code is covered without prior authorization.

Verity

`C50.912` — Malignant neoplasm of unspecified site of left female breast

ICD-10-CM

Prior Authorization

No Prior Auth Required

Code is covered without prior authorization (high confidence)

Documentation Required

Use CPT code 81540 on the claim when billing for Cancer TYPE ID.
Enter '1' in the Days/Unit field on the claim for this test.
Submit the required test identifier information using SV101-7 or SV202-7 (SV202-7 preferred) or via the NTE field if needed.
Include the appropriate DEX Z-Code identifier adjacent to the CPT code in the claim comment/narrative field for Part B claims (Loop 2400 or SV101-7 for 5010A1 837P; Box 19 for paper claims).

Key Coverage Criteria

Bill Cancer TYPE ID using CPT code 81540 (mRNA gene expression assay of 92 genes) for evaluation of tumors of unknown origin.
MammaPrint® is indicated to analyze gene expression of FFPE breast cancer tissue to assess a patient's risk for distant metastasis (early-stage breast cancer).
The test may be performed using either the FDA-cleared microarray assay or a next-generation sequencing (NGS)-based assay.
PIK3CA targeted gene sequencing is indicated to detect PIK3CA mutations in patients with hormone receptor (HR)-positive, HER2-negative, advanced or metastatic breast cancer (postmenopausal women and men) who have progressed on or after an endocrine-based regimen when results will inform treatment with alpelisib (Piqray).
Germline testing is covered when the patient has ovarian, breast, pancreatic, or prostate cancer and meets clinical indication for immediate treatment with an FDA‑approved PARP inhibitor.
Testing for deleterious variants in homologous recombination repair (HRR) genes (e.g., BRCA1, BRCA2) is covered as an aid when results will be used to determine eligibility for PARP inhibitor therapy.

20 Active Policies

A59561 — Billing and Coding: Bisphosphonate Drug Therapy

J05

L38168 — MolDX: Plasma-Based Genomic Profiling in Solid Tumors

J05

A58468 — Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers

J05

A58774 — Billing and Coding: Cosmetic and Reconstructive Surgery

J05

Have a follow-up question?

Ask Verity about documentation requirements, denial risks, or coverage in your state.

Include the appropriate DEX Z-Code identifier adjacent to the CPT code in the claim comment/narrative field for Part A claims (Line SV202-7 for 837I electronic claims; Block 80 for UB04 paper claims).

Select and report an appropriate ICD-10-CM diagnosis code on the claim that supports the medical necessity for the test.

— MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells

L38835 — MolDX: Minimal Residual Disease Testing for Cancer

J05

A57560 — Billing and Coding: MolDX: Breast Cancer Assay: Prosigna

J05

A58205 — Billing and Coding: MolDX: Phenotypic Biomarker Detection from Circulating Tumor Cells

J05

A56907 — Billing and Coding: Bisphosphonate Drug Therapy

J05

A58756 — Billing and Coding: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer

J05

A57936 — Billing and Coding: MolDX: Plasma-Based Genomic Profiling in Solid Tumors

J05

A60309 — Billing and Coding: MolDX: Non-Next Generation Sequencing Targeted Molecular Panel Tests for Predictive Testing in Cancer

J05

A57858 — Billing and Coding: MolDX: Next-Generation Sequencing for Solid Tumors

J05

L34648 — Bisphosphonate Drug Therapy

J05

A55147 — Billing and Coding: MolDX: bioTheranostics Cancer TYPE ID Update

J05

A55224 — Billing and Coding: MolDX: Germline testing for use of PARP inhibitors

J05

A55200 — Billing and Coding: MolDX: PIK3CA Gene Tests

J05

A55175 — Billing and Coding: MolDX: MammaPrint

J05

A55230 — Billing and Coding: MolDX: Oncotype DX Breast Cancer Assay

J05

L39040 — MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer

J05

C50.912 — Malignant neoplasm of unspecified site of left female breast